Market Cap 41.25M
Revenue (ttm) 3.50M
Net Income (ttm) -5.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -166.00%
Debt to Equity Ratio 0.00
Volume 101,300
Avg Vol 122,966
Day's Range N/A - N/A
Shares Out 36.19M
Stochastic %K 66%
Beta 1.00
Analysts Strong Sell
Price Target $5.67

Company Profile

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products f...

Industry: Biotechnology
Sector: Healthcare
Phone: 561 743 8333
Fax: 561 743 8343
Address:
1044 North U.S. Highway One, Suite 201, Jupiter, United States
Jirish72
Jirish72 Oct. 24 at 12:10 PM
$DYAI this is going to fly soon
1 · Reply
Glopolon
Glopolon Oct. 23 at 2:27 PM
$DYAI https://www.gurufocus.com/news/3156614/dyadic-international-dyai-receives-a-buy-rating-from-hc-wainwright-dyai-stock-news
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 10:41 AM
HC Wainwright & Co. updates rating for Dyadic International ( $DYAI ) to Buy, target set at 3.
0 · Reply
MartyCortez
MartyCortez Oct. 22 at 3:20 PM
$BYND low float $DYAI next.
0 · Reply
ed29
ed29 Oct. 19 at 1:36 PM
$DYAI @PLX_BULLS check this out.
2 · Reply
Glopolon
Glopolon Oct. 16 at 2:38 AM
$DYAI Here is a reminder about it https://www.bioprocessintl.com/deal-making/cepi-s-100-days-mission-gets-a-fungal-boost-dyadic-fbs-lead-the-way
1 · Reply
Glopolon
Glopolon Oct. 16 at 2:37 AM
$DYAI This is Rino Rappuoli, the Fondazione Biotecnopolo di Siena guy heading the $170M euro foundation study. https://royalsociety.org/people/rino-rappuoli-12894/
0 · Reply
Glopolon
Glopolon Oct. 16 at 12:42 AM
$DYAI Nirsevimab is $520 per dose. Background on RSV and Nirsevimab https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers
0 · Reply
Glopolon
Glopolon Oct. 16 at 12:40 AM
$DYAI https://d2ghdaxqb194v2.cloudfront.net/2606/198451.pdf 5-fold stronger RSV neutralization over Nirsevimab, 17-fold stronger than Clesrovimab.
0 · Reply
Glopolon
Glopolon Oct. 16 at 12:38 AM
$DYAI Dyadic posted new data in most recent pdf, from OCMS re: the RSV mAb that is being funded by Gates Foundation grant. https://www.linkedin.com/posts/ocms-bio_data-summary-activity-7376269126736019456-_kpO
0 · Reply
Latest News on DYAI
Dyadic to Present at Investor Conferences and BPI East

Sep 4, 2025, 9:00 AM EDT - 7 weeks ago

Dyadic to Present at Investor Conferences and BPI East


Dyadic International, Inc. (DYAI) Q1 2025 Earnings Call Transcript

May 14, 2025, 11:31 PM EDT - 5 months ago

Dyadic International, Inc. (DYAI) Q1 2025 Earnings Call Transcript


Dyadic to Present at World Vaccine Congress | Washington

Apr 16, 2025, 2:00 PM EDT - 6 months ago

Dyadic to Present at World Vaccine Congress | Washington


Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 10:58 PM EDT - 7 months ago

Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript


Dyadic to Attend Multiple Industry Events in March

Mar 6, 2025, 8:30 AM EST - 8 months ago

Dyadic to Attend Multiple Industry Events in March


Dyadic to Attend Industry Events in June

May 30, 2024, 4:30 PM EDT - 1 year ago

Dyadic to Attend Industry Events in June


Dyadic to Attend Industry and Investor Events in May

May 8, 2024, 8:30 AM EDT - 1 year ago

Dyadic to Attend Industry and Investor Events in May


Dyadic to Attend Industry Events in April

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Dyadic to Attend Industry Events in April


Dyadic to Attend Industry Events in March

Mar 1, 2024, 8:30 AM EST - 1 year ago

Dyadic to Attend Industry Events in March


Dyadic Attends Investor Events in December

Nov 30, 2023, 8:30 AM EST - 2 years ago

Dyadic Attends Investor Events in December


Jirish72
Jirish72 Oct. 24 at 12:10 PM
$DYAI this is going to fly soon
1 · Reply
Glopolon
Glopolon Oct. 23 at 2:27 PM
$DYAI https://www.gurufocus.com/news/3156614/dyadic-international-dyai-receives-a-buy-rating-from-hc-wainwright-dyai-stock-news
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 10:41 AM
HC Wainwright & Co. updates rating for Dyadic International ( $DYAI ) to Buy, target set at 3.
0 · Reply
MartyCortez
MartyCortez Oct. 22 at 3:20 PM
$BYND low float $DYAI next.
0 · Reply
ed29
ed29 Oct. 19 at 1:36 PM
$DYAI @PLX_BULLS check this out.
2 · Reply
Glopolon
Glopolon Oct. 16 at 2:38 AM
$DYAI Here is a reminder about it https://www.bioprocessintl.com/deal-making/cepi-s-100-days-mission-gets-a-fungal-boost-dyadic-fbs-lead-the-way
1 · Reply
Glopolon
Glopolon Oct. 16 at 2:37 AM
$DYAI This is Rino Rappuoli, the Fondazione Biotecnopolo di Siena guy heading the $170M euro foundation study. https://royalsociety.org/people/rino-rappuoli-12894/
0 · Reply
Glopolon
Glopolon Oct. 16 at 12:42 AM
$DYAI Nirsevimab is $520 per dose. Background on RSV and Nirsevimab https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers
0 · Reply
Glopolon
Glopolon Oct. 16 at 12:40 AM
$DYAI https://d2ghdaxqb194v2.cloudfront.net/2606/198451.pdf 5-fold stronger RSV neutralization over Nirsevimab, 17-fold stronger than Clesrovimab.
0 · Reply
Glopolon
Glopolon Oct. 16 at 12:38 AM
$DYAI Dyadic posted new data in most recent pdf, from OCMS re: the RSV mAb that is being funded by Gates Foundation grant. https://www.linkedin.com/posts/ocms-bio_data-summary-activity-7376269126736019456-_kpO
0 · Reply
Tarrytabby
Tarrytabby Oct. 14 at 1:45 PM
$DYAI Presentation World Vaccine Congress/ Amsterdam October 13-16, 2025 https://d2ghdaxqb194v2.cloudfront.net/2606/198451.pdf
0 · Reply
Tarrytabby
Tarrytabby Oct. 14 at 1:42 PM
$DYAI Dyadic presents at the Sidoti Small Cap Conference https://www.youtube.com/watch?v=L-x-DCX6Adw
0 · Reply
Tarrytabby
Tarrytabby Oct. 6 at 3:31 PM
$DYAI here are the news: $750,000 milestone payments - keep it up
0 · Reply
Tarrytabby
Tarrytabby Oct. 1 at 6:07 PM
$DYAI I could imagine that speculative funds/investors are stocking up here at the beginning of the quarter or there will be news.
0 · Reply
Jbaffs
Jbaffs Oct. 1 at 3:36 PM
$DYAI After tomorrows close they will have been above $1 for ten days in a row which removes the delisting risk.
2 · Reply
Jbaffs
Jbaffs Sep. 29 at 3:12 PM
$DYAI the worst stock board ever
1 · Reply
Glopolon
Glopolon Sep. 23 at 3:11 PM
$DYAI $5 target from Hallum https://m.uk.investing.com/news/analyst-ratings/craighallum-initiates-dyadic-international-stock-with-buy-rating-93CH-4254630?ampMode=1#origin=https%3A%2F%2Fwww.google.com%2F&cap=swipe,education&webview=1&dialog=1&viewport=natural&visibilityState=prerender&prerenderSize=1&viewerUrl=https%3A%2F%2Fwww.google.com%2Famp%2Fs%2Fm-uk-investing-com.cdn.ampproject.org%2Fc%2Fs%2Fm.uk.investing.com%2Fnews%2Fanalyst-ratings%2Fcraighallum-initiates-dyadic-international-stock-with-buy-rating-93CH-4254630%3FampMode=1&usqp=mq331AQIUAKwASCAAgM%25253D&amp_kit=1
0 · Reply
Glopolon
Glopolon Sep. 22 at 10:19 PM
$DYAI From Aug 1, 2005, re: Fermbox Bio https://www.cbs42.com/business/press-releases/ein-presswire/836232491/biotech-in-focus-indias-biomanufacturing-momentum-and-fermbox-bios-role-in-precision-fermentation/
0 · Reply
Glopolon
Glopolon Sep. 21 at 11:41 PM
$DYAI The ability of a protein production platform to make human like glycans opens the door to monoclonal antibody production.
0 · Reply
Glopolon
Glopolon Sep. 21 at 11:39 PM
$DYAI One of the more important advances to the C1 platform since the Dupont deal was the creation of a line that can produce human-like glycan structures. https://dyadic.com/dyadic-announces-achieving-human-like-glycan-structures-from-its-engineered-c1-cell-line/
0 · Reply
Glopolon
Glopolon Sep. 21 at 8:08 PM
$DYAI The industrial production rights have since ended, as well.. So that is opening up that arena again.
0 · Reply
Glopolon
Glopolon Sep. 21 at 8:07 PM
$DYAI It is not accurate to say they are pre-revenue. They sold their industrial production rights to Dupont for $70M in 2015, and prior to that, they were getting revenue from their protein production platform. They have refined the C1 platform since then, and they do not have a lot of R&D spend.
0 · Reply